From L-R: COO David Shoultz, CEO Daniel-Adriano Silva and CSO Alfredo Quijano Rubio (Monod Bio)

David Bak­er lab spin­out scores seed fund­ing to build a biosen­sor from en­gi­neered pro­tein

Af­ter em­bark­ing on the jour­ney of co-found­ing a biotech, Daniel-Adri­ano Sil­va was in search of his next mis­sion. He vis­it­ed David Bak­er’s lab­o­ra­to­ry at the Uni­ver­si­ty of Wash­ing­ton’s In­sti­tute for Pro­tein De­sign, where he had done his post-doc­tor­ate re­search. There, he re­con­nect­ed with Al­fre­do Qui­jano Ru­bio, who had just fin­ished his PhD and built a nov­el biosen­sor tech­nol­o­gy. The tech­nol­o­gy caught Sil­va’s at­ten­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.